nodes	percent_of_prediction	percent_of_DWPC	metapath
Ponatinib—FGFR4—embryo—polycystic ovary syndrome	0.00972	0.0322	CbGeAlD
Ponatinib—FGFR3—embryo—polycystic ovary syndrome	0.00663	0.022	CbGeAlD
Ponatinib—FGFR4—pituitary gland—polycystic ovary syndrome	0.00644	0.0213	CbGeAlD
Ponatinib—FGFR4—adrenal gland—polycystic ovary syndrome	0.00575	0.0191	CbGeAlD
Ponatinib—FGFR4—female gonad—polycystic ovary syndrome	0.00536	0.0178	CbGeAlD
Ponatinib—FGFR4—endocrine gland—polycystic ovary syndrome	0.00499	0.0165	CbGeAlD
Ponatinib—BCR—adrenal cortex—polycystic ovary syndrome	0.0047	0.0156	CbGeAlD
Ponatinib—RET—embryo—polycystic ovary syndrome	0.00457	0.0152	CbGeAlD
Ponatinib—FGFR2—embryo—polycystic ovary syndrome	0.00434	0.0144	CbGeAlD
Ponatinib—BCR—endometrium—polycystic ovary syndrome	0.0042	0.0139	CbGeAlD
Ponatinib—TEK—embryo—polycystic ovary syndrome	0.00416	0.0138	CbGeAlD
Ponatinib—FGFR3—adrenal gland—polycystic ovary syndrome	0.00392	0.013	CbGeAlD
Ponatinib—BCR—uterus—polycystic ovary syndrome	0.00387	0.0128	CbGeAlD
Ponatinib—BCR—pituitary gland—polycystic ovary syndrome	0.0038	0.0126	CbGeAlD
Ponatinib—BCR—adipose tissue—polycystic ovary syndrome	0.00379	0.0126	CbGeAlD
Ponatinib—PDGFRA—embryo—polycystic ovary syndrome	0.00377	0.0125	CbGeAlD
Ponatinib—SRC—embryo—polycystic ovary syndrome	0.0037	0.0123	CbGeAlD
Ponatinib—CYP3A4—urine—polycystic ovary syndrome	0.00357	0.0118	CbGeAlD
Ponatinib—CYP2D6—urine—polycystic ovary syndrome	0.00351	0.0116	CbGeAlD
Ponatinib—FGFR1—uterus—polycystic ovary syndrome	0.00344	0.0114	CbGeAlD
Ponatinib—LYN—endocrine gland—polycystic ovary syndrome	0.00342	0.0113	CbGeAlD
Ponatinib—TEK—adrenal cortex—polycystic ovary syndrome	0.00341	0.0113	CbGeAlD
Ponatinib—FGFR3—endocrine gland—polycystic ovary syndrome	0.0034	0.0113	CbGeAlD
Ponatinib—KDR—embryo—polycystic ovary syndrome	0.0034	0.0113	CbGeAlD
Ponatinib—BCR—adrenal gland—polycystic ovary syndrome	0.0034	0.0113	CbGeAlD
Ponatinib—FGFR1—pituitary gland—polycystic ovary syndrome	0.00338	0.0112	CbGeAlD
Ponatinib—FLT3—adrenal gland—polycystic ovary syndrome	0.00337	0.0112	CbGeAlD
Ponatinib—FGFR1—adipose tissue—polycystic ovary syndrome	0.00337	0.0112	CbGeAlD
Ponatinib—BCR—female gonad—polycystic ovary syndrome	0.00317	0.0105	CbGeAlD
Ponatinib—BCR—vagina—polycystic ovary syndrome	0.00315	0.0104	CbGeAlD
Ponatinib—FLT3—female gonad—polycystic ovary syndrome	0.00314	0.0104	CbGeAlD
Ponatinib—LCK—uterus—polycystic ovary syndrome	0.00308	0.0102	CbGeAlD
Ponatinib—TEK—endometrium—polycystic ovary syndrome	0.00305	0.0101	CbGeAlD
Ponatinib—RET—pituitary gland—polycystic ovary syndrome	0.00303	0.01	CbGeAlD
Ponatinib—FGFR1—adrenal gland—polycystic ovary syndrome	0.00302	0.01	CbGeAlD
Ponatinib—KIT—embryo—polycystic ovary syndrome	0.00302	0.01	CbGeAlD
Ponatinib—LCK—adipose tissue—polycystic ovary syndrome	0.00301	0.00999	CbGeAlD
Ponatinib—Neuropathy—Metformin—polycystic ovary syndrome	0.00297	0.0371	CcSEcCtD
Ponatinib—BCR—endocrine gland—polycystic ovary syndrome	0.00294	0.00976	CbGeAlD
Ponatinib—FGFR2—uterus—polycystic ovary syndrome	0.00293	0.00971	CbGeAlD
Ponatinib—FLT3—endocrine gland—polycystic ovary syndrome	0.00292	0.0097	CbGeAlD
Ponatinib—FGFR2—adipose tissue—polycystic ovary syndrome	0.00286	0.0095	CbGeAlD
Ponatinib—FGFR1—female gonad—polycystic ovary syndrome	0.00282	0.00934	CbGeAlD
Ponatinib—TEK—uterus—polycystic ovary syndrome	0.00281	0.00931	CbGeAlD
Ponatinib—FGFR1—vagina—polycystic ovary syndrome	0.0028	0.00928	CbGeAlD
Ponatinib—KDR—adrenal cortex—polycystic ovary syndrome	0.00279	0.00925	CbGeAlD
Ponatinib—TEK—pituitary gland—polycystic ovary syndrome	0.00276	0.00914	CbGeAlD
Ponatinib—TEK—adipose tissue—polycystic ovary syndrome	0.00275	0.0091	CbGeAlD
Ponatinib—RET—adrenal gland—polycystic ovary syndrome	0.0027	0.00897	CbGeAlD
Ponatinib—LCK—adrenal gland—polycystic ovary syndrome	0.0027	0.00897	CbGeAlD
Ponatinib—ABL1—embryo—polycystic ovary syndrome	0.00263	0.0087	CbGeAlD
Ponatinib—FGFR2—adrenal gland—polycystic ovary syndrome	0.00257	0.00852	CbGeAlD
Ponatinib—PDGFRA—uterus—polycystic ovary syndrome	0.00254	0.00843	CbGeAlD
Ponatinib—LCK—female gonad—polycystic ovary syndrome	0.00252	0.00836	CbGeAlD
Ponatinib—LCK—vagina—polycystic ovary syndrome	0.00251	0.00831	CbGeAlD
Ponatinib—KDR—endometrium—polycystic ovary syndrome	0.00249	0.00826	CbGeAlD
Ponatinib—PDGFRA—adipose tissue—polycystic ovary syndrome	0.00249	0.00825	CbGeAlD
Ponatinib—TEK—adrenal gland—polycystic ovary syndrome	0.00246	0.00817	CbGeAlD
Ponatinib—SRC—adipose tissue—polycystic ovary syndrome	0.00244	0.00809	CbGeAlD
Ponatinib—FGFR2—female gonad—polycystic ovary syndrome	0.0024	0.00794	CbGeAlD
Ponatinib—RET—endocrine gland—polycystic ovary syndrome	0.00234	0.00777	CbGeAlD
Ponatinib—Lethargy—Metformin—polycystic ovary syndrome	0.00234	0.0293	CcSEcCtD
Ponatinib—TEK—female gonad—polycystic ovary syndrome	0.0023	0.00762	CbGeAlD
Ponatinib—KDR—uterus—polycystic ovary syndrome	0.00229	0.00761	CbGeAlD
Ponatinib—Pain in extremity—Metformin—polycystic ovary syndrome	0.00229	0.0287	CcSEcCtD
Ponatinib—ABCB11—endocrine gland—polycystic ovary syndrome	0.00229	0.00759	CbGeAlD
Ponatinib—Migraine—Metformin—polycystic ovary syndrome	0.00226	0.0283	CcSEcCtD
Ponatinib—KDR—pituitary gland—polycystic ovary syndrome	0.00225	0.00747	CbGeAlD
Ponatinib—KDR—adipose tissue—polycystic ovary syndrome	0.00224	0.00744	CbGeAlD
Ponatinib—PDGFRA—adrenal gland—polycystic ovary syndrome	0.00223	0.0074	CbGeAlD
Ponatinib—FGFR2—endocrine gland—polycystic ovary syndrome	0.00223	0.00739	CbGeAlD
Ponatinib—KIT—endometrium—polycystic ovary syndrome	0.00221	0.00732	CbGeAlD
Ponatinib—SRC—adrenal gland—polycystic ovary syndrome	0.00219	0.00726	CbGeAlD
Ponatinib—ABL1—adrenal cortex—polycystic ovary syndrome	0.00215	0.00713	CbGeAlD
Ponatinib—TEK—endocrine gland—polycystic ovary syndrome	0.00214	0.00708	CbGeAlD
Ponatinib—Dehydration—Metformin—polycystic ovary syndrome	0.00213	0.0267	CcSEcCtD
Ponatinib—PDGFRA—female gonad—polycystic ovary syndrome	0.00208	0.0069	CbGeAlD
Ponatinib—Breast disorder—Metformin—polycystic ovary syndrome	0.00207	0.0259	CcSEcCtD
Ponatinib—PDGFRA—vagina—polycystic ovary syndrome	0.00207	0.00686	CbGeAlD
Ponatinib—Nasopharyngitis—Metformin—polycystic ovary syndrome	0.00205	0.0257	CcSEcCtD
Ponatinib—SRC—female gonad—polycystic ovary syndrome	0.00204	0.00677	CbGeAlD
Ponatinib—KIT—uterus—polycystic ovary syndrome	0.00203	0.00674	CbGeAlD
Ponatinib—KDR—adrenal gland—polycystic ovary syndrome	0.00201	0.00667	CbGeAlD
Ponatinib—KIT—pituitary gland—polycystic ovary syndrome	0.002	0.00662	CbGeAlD
Ponatinib—Abdominal distension—Metformin—polycystic ovary syndrome	0.002	0.025	CcSEcCtD
Ponatinib—KIT—adipose tissue—polycystic ovary syndrome	0.00199	0.00659	CbGeAlD
Ponatinib—Pancreatitis—Metformin—polycystic ovary syndrome	0.00194	0.0243	CcSEcCtD
Ponatinib—PDGFRA—endocrine gland—polycystic ovary syndrome	0.00194	0.00642	CbGeAlD
Ponatinib—Angina pectoris—Metformin—polycystic ovary syndrome	0.00193	0.0242	CcSEcCtD
Ponatinib—ABL1—endometrium—polycystic ovary syndrome	0.00192	0.00637	CbGeAlD
Ponatinib—Abdominal discomfort—Metformin—polycystic ovary syndrome	0.0019	0.0238	CcSEcCtD
Ponatinib—SRC—endocrine gland—polycystic ovary syndrome	0.0019	0.00629	CbGeAlD
Ponatinib—KDR—female gonad—polycystic ovary syndrome	0.00188	0.00622	CbGeAlD
Ponatinib—KDR—vagina—polycystic ovary syndrome	0.00187	0.00619	CbGeAlD
Ponatinib—Neutropenia—Metformin—polycystic ovary syndrome	0.00185	0.0232	CcSEcCtD
Ponatinib—Upper respiratory tract infection—Metformin—polycystic ovary syndrome	0.00184	0.0231	CcSEcCtD
Ponatinib—KIT—adrenal gland—polycystic ovary syndrome	0.00178	0.00592	CbGeAlD
Ponatinib—ABL1—uterus—polycystic ovary syndrome	0.00177	0.00587	CbGeAlD
Ponatinib—Infestation NOS—Metformin—polycystic ovary syndrome	0.00177	0.0221	CcSEcCtD
Ponatinib—Infestation—Metformin—polycystic ovary syndrome	0.00177	0.0221	CcSEcCtD
Ponatinib—KDR—endocrine gland—polycystic ovary syndrome	0.00175	0.00579	CbGeAlD
Ponatinib—ABL1—pituitary gland—polycystic ovary syndrome	0.00174	0.00576	CbGeAlD
Ponatinib—Neuropathy peripheral—Metformin—polycystic ovary syndrome	0.00173	0.0217	CcSEcCtD
Ponatinib—ABL1—adipose tissue—polycystic ovary syndrome	0.00173	0.00574	CbGeAlD
Ponatinib—Hepatobiliary disease—Metformin—polycystic ovary syndrome	0.00167	0.0209	CcSEcCtD
Ponatinib—KIT—female gonad—polycystic ovary syndrome	0.00166	0.00552	CbGeAlD
Ponatinib—KIT—vagina—polycystic ovary syndrome	0.00165	0.00548	CbGeAlD
Ponatinib—Hypoaesthesia—Metformin—polycystic ovary syndrome	0.00158	0.0198	CcSEcCtD
Ponatinib—Oedema peripheral—Metformin—polycystic ovary syndrome	0.00156	0.0196	CcSEcCtD
Ponatinib—Connective tissue disorder—Metformin—polycystic ovary syndrome	0.00156	0.0195	CcSEcCtD
Ponatinib—ABL1—adrenal gland—polycystic ovary syndrome	0.00155	0.00515	CbGeAlD
Ponatinib—KIT—endocrine gland—polycystic ovary syndrome	0.00155	0.00513	CbGeAlD
Ponatinib—Eye disorder—Metformin—polycystic ovary syndrome	0.00148	0.0186	CcSEcCtD
Ponatinib—Cardiac disorder—Metformin—polycystic ovary syndrome	0.00147	0.0184	CcSEcCtD
Ponatinib—Flushing—Metformin—polycystic ovary syndrome	0.00147	0.0184	CcSEcCtD
Ponatinib—ABL1—female gonad—polycystic ovary syndrome	0.00145	0.0048	CbGeAlD
Ponatinib—Angiopathy—Metformin—polycystic ovary syndrome	0.00144	0.018	CcSEcCtD
Ponatinib—ABL1—vagina—polycystic ovary syndrome	0.00144	0.00477	CbGeAlD
Ponatinib—Mediastinal disorder—Metformin—polycystic ovary syndrome	0.00143	0.0179	CcSEcCtD
Ponatinib—Chills—Metformin—polycystic ovary syndrome	0.00142	0.0178	CcSEcCtD
Ponatinib—Erythema—Metformin—polycystic ovary syndrome	0.00138	0.0173	CcSEcCtD
Ponatinib—Malnutrition—Metformin—polycystic ovary syndrome	0.00138	0.0173	CcSEcCtD
Ponatinib—ABCG2—adrenal cortex—polycystic ovary syndrome	0.00136	0.0045	CbGeAlD
Ponatinib—ABL1—endocrine gland—polycystic ovary syndrome	0.00135	0.00447	CbGeAlD
Ponatinib—Muscle spasms—Metformin—polycystic ovary syndrome	0.00133	0.0166	CcSEcCtD
Ponatinib—Vision blurred—Metformin—polycystic ovary syndrome	0.0013	0.0163	CcSEcCtD
Ponatinib—CYP2C8—endometrium—polycystic ovary syndrome	0.00125	0.00413	CbGeAlD
Ponatinib—ABCG2—endometrium—polycystic ovary syndrome	0.00121	0.00402	CbGeAlD
Ponatinib—Hypertension—Metformin—polycystic ovary syndrome	0.00119	0.0149	CcSEcCtD
Ponatinib—Myalgia—Metformin—polycystic ovary syndrome	0.00118	0.0147	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.00117	0.0146	CcSEcCtD
Ponatinib—Oedema—Metformin—polycystic ovary syndrome	0.00113	0.0141	CcSEcCtD
Ponatinib—CYP2C8—pituitary gland—polycystic ovary syndrome	0.00113	0.00374	CbGeAlD
Ponatinib—Infection—Metformin—polycystic ovary syndrome	0.00112	0.014	CcSEcCtD
Ponatinib—ABCG2—uterus—polycystic ovary syndrome	0.00112	0.0037	CbGeAlD
Ponatinib—Nervous system disorder—Metformin—polycystic ovary syndrome	0.00111	0.0138	CcSEcCtD
Ponatinib—Thrombocytopenia—Metformin—polycystic ovary syndrome	0.0011	0.0138	CcSEcCtD
Ponatinib—ABCG2—pituitary gland—polycystic ovary syndrome	0.0011	0.00363	CbGeAlD
Ponatinib—Skin disorder—Metformin—polycystic ovary syndrome	0.0011	0.0137	CcSEcCtD
Ponatinib—ABCG2—adipose tissue—polycystic ovary syndrome	0.00109	0.00362	CbGeAlD
Ponatinib—Hyperhidrosis—Metformin—polycystic ovary syndrome	0.00109	0.0136	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.00103	0.0129	CcSEcCtD
Ponatinib—CYP3A5—adipose tissue—polycystic ovary syndrome	0.00101	0.00336	CbGeAlD
Ponatinib—Paraesthesia—Metformin—polycystic ovary syndrome	0.00101	0.0127	CcSEcCtD
Ponatinib—Dyspnoea—Metformin—polycystic ovary syndrome	0.00101	0.0126	CcSEcCtD
Ponatinib—Dyspepsia—Metformin—polycystic ovary syndrome	0.000993	0.0124	CcSEcCtD
Ponatinib—Decreased appetite—Metformin—polycystic ovary syndrome	0.00098	0.0123	CcSEcCtD
Ponatinib—ABCG2—adrenal gland—polycystic ovary syndrome	0.000979	0.00325	CbGeAlD
Ponatinib—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.000974	0.0122	CcSEcCtD
Ponatinib—Fatigue—Metformin—polycystic ovary syndrome	0.000972	0.0122	CcSEcCtD
Ponatinib—Constipation—Metformin—polycystic ovary syndrome	0.000964	0.0121	CcSEcCtD
Ponatinib—CYP2C8—vagina—polycystic ovary syndrome	0.000933	0.0031	CbGeAlD
Ponatinib—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.000922	0.0115	CcSEcCtD
Ponatinib—ABCG2—female gonad—polycystic ovary syndrome	0.000913	0.00303	CbGeAlD
Ponatinib—ABCG2—vagina—polycystic ovary syndrome	0.000908	0.00301	CbGeAlD
Ponatinib—Abdominal pain—Metformin—polycystic ovary syndrome	0.000891	0.0112	CcSEcCtD
Ponatinib—CYP2C8—endocrine gland—polycystic ovary syndrome	0.000873	0.0029	CbGeAlD
Ponatinib—CYP3A5—female gonad—polycystic ovary syndrome	0.000848	0.00281	CbGeAlD
Ponatinib—CYP3A5—vagina—polycystic ovary syndrome	0.000842	0.00279	CbGeAlD
Ponatinib—ABCB1—embryo—polycystic ovary syndrome	0.000816	0.00271	CbGeAlD
Ponatinib—Asthenia—Metformin—polycystic ovary syndrome	0.000809	0.0101	CcSEcCtD
Ponatinib—Pruritus—Metformin—polycystic ovary syndrome	0.000798	0.00998	CcSEcCtD
Ponatinib—CYP3A5—endocrine gland—polycystic ovary syndrome	0.000788	0.00261	CbGeAlD
Ponatinib—Diarrhoea—Metformin—polycystic ovary syndrome	0.000772	0.00966	CcSEcCtD
Ponatinib—Dizziness—Metformin—polycystic ovary syndrome	0.000746	0.00933	CcSEcCtD
Ponatinib—Vomiting—Metformin—polycystic ovary syndrome	0.000717	0.00897	CcSEcCtD
Ponatinib—Rash—Metformin—polycystic ovary syndrome	0.000711	0.0089	CcSEcCtD
Ponatinib—Dermatitis—Metformin—polycystic ovary syndrome	0.00071	0.00889	CcSEcCtD
Ponatinib—Headache—Metformin—polycystic ovary syndrome	0.000706	0.00884	CcSEcCtD
Ponatinib—Nausea—Metformin—polycystic ovary syndrome	0.00067	0.00838	CcSEcCtD
Ponatinib—ABCB1—adrenal cortex—polycystic ovary syndrome	0.000669	0.00222	CbGeAlD
Ponatinib—CYP2D6—female gonad—polycystic ovary syndrome	0.000626	0.00208	CbGeAlD
Ponatinib—ABCB1—endometrium—polycystic ovary syndrome	0.000597	0.00198	CbGeAlD
Ponatinib—CYP3A4—endocrine gland—polycystic ovary syndrome	0.000592	0.00196	CbGeAlD
Ponatinib—CYP2D6—endocrine gland—polycystic ovary syndrome	0.000582	0.00193	CbGeAlD
Ponatinib—ABCB1—uterus—polycystic ovary syndrome	0.00055	0.00183	CbGeAlD
Ponatinib—ABCB1—pituitary gland—polycystic ovary syndrome	0.000541	0.00179	CbGeAlD
Ponatinib—ABCB1—adipose tissue—polycystic ovary syndrome	0.000538	0.00179	CbGeAlD
Ponatinib—ABCB1—adrenal gland—polycystic ovary syndrome	0.000483	0.0016	CbGeAlD
Ponatinib—ABCB1—female gonad—polycystic ovary syndrome	0.00045	0.00149	CbGeAlD
Ponatinib—ABCB1—vagina—polycystic ovary syndrome	0.000448	0.00148	CbGeAlD
Ponatinib—ABCB1—endocrine gland—polycystic ovary syndrome	0.000419	0.00139	CbGeAlD
Ponatinib—LCK—Disease—MTHFR—polycystic ovary syndrome	1.41e-05	2.28e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—RRM2—polycystic ovary syndrome	1.4e-05	2.27e-05	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—PPARG—polycystic ovary syndrome	1.4e-05	2.27e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—AKR1C3—polycystic ovary syndrome	1.4e-05	2.26e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—IRS2—polycystic ovary syndrome	1.4e-05	2.26e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—NRG1—polycystic ovary syndrome	1.39e-05	2.24e-05	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—POMC—polycystic ovary syndrome	1.38e-05	2.24e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—CYP17A1—polycystic ovary syndrome	1.38e-05	2.23e-05	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—INS—polycystic ovary syndrome	1.38e-05	2.22e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—IRS2—polycystic ovary syndrome	1.37e-05	2.22e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—AKR1C1—polycystic ovary syndrome	1.37e-05	2.22e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—LEP—polycystic ovary syndrome	1.37e-05	2.21e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—LHB—polycystic ovary syndrome	1.37e-05	2.21e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.36e-05	2.2e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.36e-05	2.2e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—GNAS—polycystic ovary syndrome	1.36e-05	2.2e-05	CbGpPWpGaD
Ponatinib—FGFR2—Innate Immune System—IL6—polycystic ovary syndrome	1.35e-05	2.19e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—YAP1—polycystic ovary syndrome	1.35e-05	2.19e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PLAT—polycystic ovary syndrome	1.35e-05	2.19e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—GHRL—polycystic ovary syndrome	1.35e-05	2.19e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—NGFR—polycystic ovary syndrome	1.34e-05	2.17e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—LEP—polycystic ovary syndrome	1.34e-05	2.17e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—IRS2—polycystic ovary syndrome	1.34e-05	2.17e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—NRG1—polycystic ovary syndrome	1.34e-05	2.16e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—HSD3B2—polycystic ovary syndrome	1.33e-05	2.16e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PRL—polycystic ovary syndrome	1.33e-05	2.15e-05	CbGpPWpGaD
Ponatinib—KIT—Innate Immune System—IL6—polycystic ovary syndrome	1.33e-05	2.15e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—VEGFA—polycystic ovary syndrome	1.32e-05	2.13e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—IRS2—polycystic ovary syndrome	1.3e-05	2.1e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—NAMPT—polycystic ovary syndrome	1.3e-05	2.1e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—IRS2—polycystic ovary syndrome	1.3e-05	2.1e-05	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—VEGFA—polycystic ovary syndrome	1.29e-05	2.09e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—NCOR1—polycystic ovary syndrome	1.29e-05	2.09e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—AKR1C1—polycystic ovary syndrome	1.29e-05	2.09e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	1.29e-05	2.09e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—ATF1—polycystic ovary syndrome	1.29e-05	2.09e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—IRS2—polycystic ovary syndrome	1.29e-05	2.08e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—CRP—polycystic ovary syndrome	1.29e-05	2.08e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—CYP11A1—polycystic ovary syndrome	1.28e-05	2.07e-05	CbGpPWpGaD
Ponatinib—SRC—Axon guidance—IL6—polycystic ovary syndrome	1.28e-05	2.07e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	1.27e-05	2.06e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—LEP—polycystic ovary syndrome	1.27e-05	2.06e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PNPLA2—polycystic ovary syndrome	1.27e-05	2.06e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—LEP—polycystic ovary syndrome	1.27e-05	2.05e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—IRS1—polycystic ovary syndrome	1.27e-05	2.05e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—ADRB2—polycystic ovary syndrome	1.26e-05	2.04e-05	CbGpPWpGaD
Ponatinib—FGFR1—Innate Immune System—IL6—polycystic ovary syndrome	1.26e-05	2.04e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—SULT2A1—polycystic ovary syndrome	1.26e-05	2.04e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Innate Immune System—IL6—polycystic ovary syndrome	1.26e-05	2.04e-05	CbGpPWpGaD
Ponatinib—LYN—Developmental Biology—IL6—polycystic ovary syndrome	1.26e-05	2.03e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TCF7L2—polycystic ovary syndrome	1.26e-05	2.03e-05	CbGpPWpGaD
Ponatinib—ABL1—Developmental Biology—IL6—polycystic ovary syndrome	1.25e-05	2.02e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—BCL2—polycystic ovary syndrome	1.25e-05	2.02e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—MTHFR—polycystic ovary syndrome	1.25e-05	2.02e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—BCL2—polycystic ovary syndrome	1.24e-05	2.01e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—CYP1A1—polycystic ovary syndrome	1.23e-05	1.98e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—RRM2—polycystic ovary syndrome	1.22e-05	1.98e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—IRS1—polycystic ovary syndrome	1.22e-05	1.97e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—AKR1C3—polycystic ovary syndrome	1.21e-05	1.96e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—SRD5A1—polycystic ovary syndrome	1.21e-05	1.95e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—IRS1—polycystic ovary syndrome	1.2e-05	1.94e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—CYP17A1—polycystic ovary syndrome	1.19e-05	1.93e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—TH—polycystic ovary syndrome	1.19e-05	1.93e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—NGFR—polycystic ovary syndrome	1.19e-05	1.92e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—SULT2A1—polycystic ovary syndrome	1.19e-05	1.92e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—IRS2—polycystic ovary syndrome	1.19e-05	1.92e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PRL—polycystic ovary syndrome	1.18e-05	1.91e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—YAP1—polycystic ovary syndrome	1.18e-05	1.91e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—POMC—polycystic ovary syndrome	1.17e-05	1.9e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—AKT2—polycystic ovary syndrome	1.17e-05	1.9e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—GNAS—polycystic ovary syndrome	1.17e-05	1.9e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—IRS1—polycystic ovary syndrome	1.17e-05	1.89e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—INS—polycystic ovary syndrome	1.17e-05	1.89e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—SLC2A4—polycystic ovary syndrome	1.16e-05	1.87e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—POMC—polycystic ovary syndrome	1.15e-05	1.86e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—RRM2—polycystic ovary syndrome	1.15e-05	1.86e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—STAR—polycystic ovary syndrome	1.15e-05	1.86e-05	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—IL6—polycystic ovary syndrome	1.15e-05	1.86e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—INS—polycystic ovary syndrome	1.15e-05	1.85e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—IRS2—polycystic ovary syndrome	1.15e-05	1.85e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—MTHFR—polycystic ovary syndrome	1.14e-05	1.85e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—IRS1—polycystic ovary syndrome	1.14e-05	1.84e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—IRS1—polycystic ovary syndrome	1.13e-05	1.83e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—NAMPT—polycystic ovary syndrome	1.13e-05	1.83e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—IGF1—polycystic ovary syndrome	1.13e-05	1.83e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—AKT2—polycystic ovary syndrome	1.13e-05	1.82e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—IRS1—polycystic ovary syndrome	1.12e-05	1.81e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—LEP—polycystic ovary syndrome	1.12e-05	1.81e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—INS—polycystic ovary syndrome	1.12e-05	1.81e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—ADRB2—polycystic ovary syndrome	1.12e-05	1.81e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—CYP11A1—polycystic ovary syndrome	1.12e-05	1.81e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.12e-05	1.81e-05	CbGpPWpGaD
Ponatinib—LYN—Innate Immune System—IL6—polycystic ovary syndrome	1.11e-05	1.8e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—YAP1—polycystic ovary syndrome	1.11e-05	1.8e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—IGF1—polycystic ovary syndrome	1.11e-05	1.79e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—AKT2—polycystic ovary syndrome	1.11e-05	1.79e-05	CbGpPWpGaD
Ponatinib—ABL1—Innate Immune System—IL6—polycystic ovary syndrome	1.11e-05	1.79e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—NRG1—polycystic ovary syndrome	1.1e-05	1.77e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—POMC—polycystic ovary syndrome	1.09e-05	1.77e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—POMC—polycystic ovary syndrome	1.09e-05	1.76e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—CYP19A1—polycystic ovary syndrome	1.09e-05	1.76e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—INS—polycystic ovary syndrome	1.09e-05	1.76e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—INS—polycystic ovary syndrome	1.09e-05	1.76e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—AKT2—polycystic ovary syndrome	1.08e-05	1.75e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.07e-05	1.73e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.07e-05	1.73e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—NAMPT—polycystic ovary syndrome	1.07e-05	1.72e-05	CbGpPWpGaD
Ponatinib—FGFR3—Disease—IL6—polycystic ovary syndrome	1.06e-05	1.71e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—AKR1C3—polycystic ovary syndrome	1.06e-05	1.71e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—CYP11A1—polycystic ovary syndrome	1.05e-05	1.7e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.05e-05	1.7e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—IGF1—polycystic ovary syndrome	1.05e-05	1.7e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—AKT2—polycystic ovary syndrome	1.05e-05	1.7e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—IGF1—polycystic ovary syndrome	1.05e-05	1.7e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—AKT2—polycystic ovary syndrome	1.05e-05	1.7e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—CYP17A1—polycystic ovary syndrome	1.04e-05	1.68e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—AKT2—polycystic ovary syndrome	1.04e-05	1.68e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—GNAS—polycystic ovary syndrome	1.04e-05	1.68e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—IRS1—polycystic ovary syndrome	1.04e-05	1.68e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—TH—polycystic ovary syndrome	1.03e-05	1.67e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—SERPINE1—polycystic ovary syndrome	1.03e-05	1.66e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—HMMR—polycystic ovary syndrome	1.03e-05	1.66e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—BCL2—polycystic ovary syndrome	1.02e-05	1.66e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—SLC2A4—polycystic ovary syndrome	1e-05	1.62e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—IL6—polycystic ovary syndrome	1e-05	1.62e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—IRS1—polycystic ovary syndrome	1e-05	1.62e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1e-05	1.62e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—SERPINE1—polycystic ovary syndrome	9.97e-06	1.61e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—AKR1C3—polycystic ovary syndrome	9.95e-06	1.61e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—INS—polycystic ovary syndrome	9.92e-06	1.6e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—NCOR1—polycystic ovary syndrome	9.88e-06	1.6e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—CYP17A1—polycystic ovary syndrome	9.79e-06	1.58e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—HSD3B1—polycystic ovary syndrome	9.79e-06	1.58e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—GNAS—polycystic ovary syndrome	9.73e-06	1.57e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—NRG1—polycystic ovary syndrome	9.7e-06	1.57e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—POMC—polycystic ovary syndrome	9.63e-06	1.56e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—AKT2—polycystic ovary syndrome	9.59e-06	1.55e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—INS—polycystic ovary syndrome	9.57e-06	1.55e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—CYP19A1—polycystic ovary syndrome	9.44e-06	1.53e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IRS2—polycystic ovary syndrome	9.39e-06	1.52e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—VEGFA—polycystic ovary syndrome	9.34e-06	1.51e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PPARG—polycystic ovary syndrome	9.27e-06	1.5e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—NCOR1—polycystic ovary syndrome	9.27e-06	1.5e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—IGF1—polycystic ovary syndrome	9.26e-06	1.5e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—AKT2—polycystic ovary syndrome	9.25e-06	1.5e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—LEP—polycystic ovary syndrome	9.19e-06	1.49e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—POMC—polycystic ovary syndrome	9.14e-06	1.48e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—IL6—polycystic ovary syndrome	9.13e-06	1.48e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—SERPINE1—polycystic ovary syndrome	9.11e-06	1.47e-05	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—IL6—polycystic ovary syndrome	9.11e-06	1.47e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—INS—polycystic ovary syndrome	9.09e-06	1.47e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—BCL2—polycystic ovary syndrome	9.07e-06	1.47e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—TH—polycystic ovary syndrome	8.99e-06	1.45e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—LHB—polycystic ovary syndrome	8.93e-06	1.44e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—SERPINE1—polycystic ovary syndrome	8.79e-06	1.42e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—CYP1A1—polycystic ovary syndrome	8.79e-06	1.42e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—SLC2A4—polycystic ovary syndrome	8.75e-06	1.41e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—HSD3B2—polycystic ovary syndrome	8.72e-06	1.41e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—TH—polycystic ovary syndrome	8.47e-06	1.37e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—AKR1C1—polycystic ovary syndrome	8.45e-06	1.37e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—GNAS—polycystic ovary syndrome	8.43e-06	1.36e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IRS2—polycystic ovary syndrome	8.31e-06	1.34e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—SLC2A4—polycystic ovary syndrome	8.24e-06	1.33e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—CYP19A1—polycystic ovary syndrome	8.23e-06	1.33e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IRS1—polycystic ovary syndrome	8.2e-06	1.32e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—MTHFR—polycystic ovary syndrome	8.19e-06	1.32e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—LEP—polycystic ovary syndrome	8.13e-06	1.31e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—IL6—polycystic ovary syndrome	8.06e-06	1.3e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—NCOR1—polycystic ovary syndrome	8.03e-06	1.3e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—POMC—polycystic ovary syndrome	7.89e-06	1.28e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—IL6—polycystic ovary syndrome	7.89e-06	1.28e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—INS—polycystic ovary syndrome	7.85e-06	1.27e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—SULT2A1—polycystic ovary syndrome	7.78e-06	1.26e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—CYP19A1—polycystic ovary syndrome	7.75e-06	1.25e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—IL6—polycystic ovary syndrome	7.75e-06	1.25e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—CYP1A1—polycystic ovary syndrome	7.61e-06	1.23e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IGF1—polycystic ovary syndrome	7.59e-06	1.23e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—AKT2—polycystic ovary syndrome	7.59e-06	1.23e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—RRM2—polycystic ovary syndrome	7.53e-06	1.22e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—IL6—polycystic ovary syndrome	7.42e-06	1.2e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—VEGFA—polycystic ovary syndrome	7.38e-06	1.19e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—IL6—polycystic ovary syndrome	7.36e-06	1.19e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—GNAS—polycystic ovary syndrome	7.34e-06	1.19e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—IL6—polycystic ovary syndrome	7.34e-06	1.19e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—IL6—polycystic ovary syndrome	7.29e-06	1.18e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—YAP1—polycystic ovary syndrome	7.26e-06	1.17e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IRS1—polycystic ovary syndrome	7.25e-06	1.17e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—VEGFA—polycystic ovary syndrome	7.24e-06	1.17e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—SERPINE1—polycystic ovary syndrome	7.21e-06	1.17e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—IL6—polycystic ovary syndrome	7.16e-06	1.16e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—MTHFR—polycystic ovary syndrome	7.09e-06	1.15e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—NCOR1—polycystic ovary syndrome	6.99e-06	1.13e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—POMC—polycystic ovary syndrome	6.99e-06	1.13e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—NAMPT—polycystic ovary syndrome	6.97e-06	1.13e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—INS—polycystic ovary syndrome	6.95e-06	1.12e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—GNAS—polycystic ovary syndrome	6.92e-06	1.12e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CYP11A1—polycystic ovary syndrome	6.89e-06	1.11e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—VEGFA—polycystic ovary syndrome	6.88e-06	1.11e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—VEGFA—polycystic ovary syndrome	6.86e-06	1.11e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—IL6—polycystic ovary syndrome	6.79e-06	1.1e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—IL6—polycystic ovary syndrome	6.77e-06	1.1e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IGF1—polycystic ovary syndrome	6.72e-06	1.09e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—AKT2—polycystic ovary syndrome	6.72e-06	1.09e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PPARG—polycystic ovary syndrome	6.64e-06	1.07e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—CYP1A1—polycystic ovary syndrome	6.63e-06	1.07e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—NCOR1—polycystic ovary syndrome	6.59e-06	1.07e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—POMC—polycystic ovary syndrome	6.55e-06	1.06e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—INS—polycystic ovary syndrome	6.51e-06	1.05e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—AKR1C3—polycystic ovary syndrome	6.5e-06	1.05e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—IL6—polycystic ovary syndrome	6.47e-06	1.05e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—IL6—polycystic ovary syndrome	6.46e-06	1.04e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—IL6—polycystic ovary syndrome	6.44e-06	1.04e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CYP17A1—polycystic ovary syndrome	6.4e-06	1.04e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—SERPINE1—polycystic ovary syndrome	6.38e-06	1.03e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—CYP1A1—polycystic ovary syndrome	6.25e-06	1.01e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—MTHFR—polycystic ovary syndrome	6.18e-06	9.99e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—VEGFA—polycystic ovary syndrome	6.05e-06	9.78e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—MTHFR—polycystic ovary syndrome	5.82e-06	9.42e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PPARG—polycystic ovary syndrome	5.75e-06	9.3e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—POMC—polycystic ovary syndrome	5.67e-06	9.17e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—INS—polycystic ovary syndrome	5.64e-06	9.12e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—TH—polycystic ovary syndrome	5.54e-06	8.96e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—SLC2A4—polycystic ovary syndrome	5.39e-06	8.71e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—IL6—polycystic ovary syndrome	5.3e-06	8.58e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—IL6—polycystic ovary syndrome	5.1e-06	8.25e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CYP19A1—polycystic ovary syndrome	5.07e-06	8.19e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PPARG—polycystic ovary syndrome	5.01e-06	8.1e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—IL6—polycystic ovary syndrome	5.01e-06	8.1e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—VEGFA—polycystic ovary syndrome	4.96e-06	8.02e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—POMC—polycystic ovary syndrome	4.94e-06	7.99e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—INS—polycystic ovary syndrome	4.92e-06	7.95e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—IL6—polycystic ovary syndrome	4.9e-06	7.92e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—IL6—polycystic ovary syndrome	4.76e-06	7.69e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—IL6—polycystic ovary syndrome	4.74e-06	7.67e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PPARG—polycystic ovary syndrome	4.72e-06	7.64e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—IL6—polycystic ovary syndrome	4.7e-06	7.59e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—POMC—polycystic ovary syndrome	4.66e-06	7.53e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—INS—polycystic ovary syndrome	4.63e-06	7.49e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GNAS—polycystic ovary syndrome	4.52e-06	7.31e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—VEGFA—polycystic ovary syndrome	4.39e-06	7.1e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—IL6—polycystic ovary syndrome	4.34e-06	7.01e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—NCOR1—polycystic ovary syndrome	4.31e-06	6.97e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—IL6—polycystic ovary syndrome	4.18e-06	6.76e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CYP1A1—polycystic ovary syndrome	4.08e-06	6.6e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—MTHFR—polycystic ovary syndrome	3.81e-06	6.16e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IL6—polycystic ovary syndrome	3.43e-06	5.54e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PPARG—polycystic ovary syndrome	3.09e-06	4.99e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—POMC—polycystic ovary syndrome	3.05e-06	4.92e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IL6—polycystic ovary syndrome	3.04e-06	4.91e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—INS—polycystic ovary syndrome	3.03e-06	4.9e-06	CbGpPWpGaD
